The Security of Onshore Manufacturing
03Jul

The Security of Onshore Manufacturing

Global supply chain security is a serious concern in the pharmaceutical industry, leading many organizations to onshore drug developme
Noramco CEO Lee Karras discusses “3 Key Trends” impacting the CDMO industry
03Jun

Noramco CEO Lee Karras discusses “3 Key Trends” impacting the CDMO industry

Noramco CEO Lee Karras joined Contract Pharma for a roundtable with other thought leaders across the pharmaceutical services sector to
Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
19Mar

Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech

Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, today announced its l
Nitrosamine Testing Deadline is August 1, 2025. Are you ready?
05Mar

Nitrosamine Testing Deadline is August 1, 2025. Are you ready?

Testing for the presence of nitrosamines on pharmaceutical drug products will be a requirement clinical development starting August 1,
Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
14Mar

Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider

Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, today announced its l
Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
02Nov

Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit

Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today
Connect With Us